Update on the treatment of type 2 diabetes mellitus

被引:427
|
作者
Jose Marin-Penalver, Juan [1 ]
Martin-Timon, Iciar [1 ]
Sevillano-Collantes, Cristina [1 ]
Javier del Canizo-Gomez, Francisco [1 ]
机构
[1] Univ Complutense, Endocrinol Sect, Hosp Univ Infanta Leonor, Fac Med, Avda Gran Via Este 80, Madrid 28031, Spain
关键词
Type 2 diabetes mellitus; Treatment; Oral antidiabetic agents; Injectable antidiabetic agents; Older people; Renal impairment; Future treatments;
D O I
10.4239/wjd.v7.i17.354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifestyle changes. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.
引用
收藏
页码:354 / 395
页数:42
相关论文
共 50 条
  • [1] Exercise and the treatment of type 2 diabetes mellitus - An update
    Eriksson, JG
    [J]. SPORTS MEDICINE, 1999, 27 (06) : 381 - 391
  • [2] Dapagliflozin for the treatment of type 2 diabetes mellitus - an update
    Nicholson, Martha K.
    Ghazal Asswad, Randa
    Wilding, John P. H.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (17) : 2303 - 2310
  • [3] The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update
    Katsiki, N.
    Athyros, V. G.
    Karagiannis, A.
    Mikhailidis, D. P.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (24) : 3565 - 3565
  • [4] The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update
    Katsiki, Niki
    Athyros, Vasilios G.
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (22) : 3665 - 3674
  • [5] Type 2 diabetes mellitus: Update on diagnosis, pathophysiology, and treatment
    Mahler, RJ
    Adler, ML
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (04): : 1165 - 1171
  • [6] Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm
    Green, J.
    Feinglos, M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 : 3 - 11
  • [7] Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus
    Sundeep Khosla
    Parinya Samakkarnthai
    David G. Monroe
    Joshua N. Farr
    [J]. Nature Reviews Endocrinology, 2021, 17 : 685 - 697
  • [8] Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)
    Clodi, Martin
    Abrahamian, Heidemarie
    Brath, Helmut
    Schernthaner, Guntram
    Brix, Johann
    Ludvik, Bernhard
    Drexel, Heinz H.
    Saely, Christoph
    Fasching, Peter
    Rega-Kaun, Gersina
    Foeger, Bernhard
    Francesconi, Claudia
    Froehlich-Reiterer, Elke
    Kautzky-Willer, Alexandra
    Harreiter, Juergen
    Luger, Anton
    Resl, Michael
    Riedl, Michaela
    Winhofer, Yvonne E.
    Hofer, Sabine
    Hoppichler, Friedrich
    Huber, Joakim
    Kaser, Susanne
    Ress, Claudia
    Lechleitner, Monika
    Aberer, Felix K.
    Mader, Julia
    Sourij, Harald
    Toplak, Hermann
    Paulweber, Bernhard
    Stechemesser, Lars
    Pieber, Thomas
    Prager, Rudolf
    Stingl, Harald
    Stulnig, Thomas
    Rami-Merhar, Birgit
    Roden, Michael
    Schelkshorn, Christian
    Wascher, Thomas C.
    Weitgasser, Raimund
    Zlamal-Fortunat, Sandra
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 (SUPPL 1) : 32 - 44
  • [9] Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus
    Khosla, Sundeep
    Samakkarnthai, Parinya
    Monroe, David G.
    Farr, Joshua N.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2021, 17 (11) : 685 - 697
  • [10] Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)
    Clodi, Martin
    Abrahamian, Heidemarie
    Brath, Helmut
    Brix, Johanna
    Drexel, Heinz
    Fasching, Peter
    Foeger, Bernhard
    Francesconi, Claudia
    Froehlich-Reiterer, Elke
    Harreiter, Juergen
    Hofer, Sabine E.
    Hoppichler, Friedrich
    Huber, Joakim
    Kaser, Susanne
    Kautzky-Willer, Alexandra
    Lechleitner, Monika
    Ludvik, Bernhard
    Luger, Anton
    Mader, Julia K.
    Paulweber, Bernhard
    Pieber, Thomas
    Prager, Rudolf
    Rami-Merhar, Birgit
    Resl, Michael
    Riedl, Michaela
    Roden, Michael
    Saely, Christoph H.
    Schelkshorn, Christian
    Schernthaner, Guntram
    Sourij, Harald
    Stechemesser, Lars
    Stingl, Harald
    Toplak, Hermann
    Wascher, Thomas C.
    Weitgasser, Raimund
    Winhofer-Stoeckl, Yvonne
    Zlamal-Fortunat, Sandra
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 (Suppl 1) : 27 - 38